ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $150,000 G-Rex Grant to Verismo Therapeutics, a clinical-stage CAR T company. This grant, part of ScaleReady's $20 million program, aims to optimize the development and manufacturing of Verismo's KIR-CAR platform using G-Rex technology.
The grant will support Verismo in transitioning their active and future pipeline to G-Rex, enhancing efficiency and cost-effectiveness in cell therapy production. As part of the grant, Verismo will evaluate critical reagents from Bio-Techne, including GMP cytokines and the new ProPak GMP Cytokines line, estimated to be commercially available by the end of 2024.
ScaleReady, in collaborazione con Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) e CellReady, ha assegnato un G-Rex Grant di $150.000 a Verismo Therapeutics, un'azienda in fase clinica nel campo delle CAR T. Questo finanziamento, parte del programma di $20 milioni di ScaleReady, mira a ottimizzare lo sviluppo e la produzione della piattaforma KIR-CAR di Verismo utilizzando la tecnologia G-Rex.
Il grant supporterà Verismo nella transizione del loro pipeline attivo e futuro a G-Rex, migliorando l'efficienza e la convenienza economica nella produzione di terapie cellulari. Come parte del grant, Verismo valuterà i reagenti critici di Bio-Techne, inclusi i citochine GMP e la nuova linea di citochine ProPak GMP, che si prevede sarà commercialmente disponibile entro la fine del 2024.
ScaleReady, en colaboración con Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) y CellReady, ha otorgado una subvención G-Rex de $150,000 a Verismo Therapeutics, una empresa en etapa clínica de CAR T. Esta subvención, parte del programa de $20 millones de ScaleReady, tiene como objetivo optimizar el desarrollo y la fabricación de la plataforma KIR-CAR de Verismo utilizando la tecnología G-Rex.
La subvención apoyará a Verismo en la transición de su pipeline activo y futuro a G-Rex, mejorando la eficiencia y la rentabilidad en la producción de terapias celulares. Como parte de la subvención, Verismo evaluará reactivos críticos de Bio-Techne, incluidos citoquinas GMP y la nueva línea de Citoquinas ProPak GMP, que se estima estarán disponibles comercialmente a finales de 2024.
ScaleReady는 Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), CellReady와 협력하여 Verismo Therapeutics에 $150,000 G-Rex Grant를 수여했습니다. 이 보조금은 ScaleReady의 $20 million program의 일환으로, Verismo의 KIR-CAR 플랫폼 개발 및 제조를 G-Rex 기술을 사용하여 최적화하는 것을 목표로 합니다.
이 보조금은 Verismo가 현재 및 미래 파이프라인을 G-Rex로 전환하는 데 도움을 주며, 세포 치료제 생산의 효율성과 비용 효과성을 개선합니다. 보조금의 일환으로 Verismo는 Bio-Techne의 GMP 사이토카인과 2024년 말 상용 가능할 것으로 예상되는 새로운 ProPak GMP 사이토카인 라인을 포함한 중요한 시약을 평가할 것입니다.
ScaleReady, en collaboration avec Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) et CellReady, a accordé une bourse G-Rex de 150 000 $ à Verismo Therapeutics, une entreprise de CAR T en phase clinique. Cette bourse, faisant partie du programme de 20 millions de dollars de ScaleReady, vise à optimiser le développement et la fabrication de la plateforme KIR-CAR de Verismo grâce à la technologie G-Rex.
La bourse soutiendra Verismo dans la transition de son pipeline actif et futur vers G-Rex, améliorant l'efficacité et la rentabilité de la production de thérapies cellulaires. Dans le cadre de la bourse, Verismo évaluera des réactifs critiques de Bio-Techne, y compris des cytokines GMP et la nouvelle ligne de cytokines GMP ProPak, qui devraient être commercialement disponibles d'ici fin 2024.
ScaleReady hat in Zusammenarbeit mit Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) und CellReady einen $150.000 G-Rex Grant an Verismo Therapeutics, ein Unternehmen in der klinischen Phase der CAR T, vergeben. Dieses Stipendium, Teil des $20-Millionen-Programms von ScaleReady, zielt darauf ab, die Entwicklung und Herstellung von Verismos KIR-CAR-Plattform mithilfe der G-Rex-Technologie zu optimieren.
Das Stipendium wird Verismo dabei unterstützen, ihre aktive und zukünftige Pipeline auf G-Rex umzustellen, wodurch die Effizienz und Kosteneffektivität in der Produktion von Zelltherapien verbessert wird. Im Rahmen des Stipendiums wird Verismo wichtige Reagenzien von Bio-Techne bewerten, darunter GMP-Zytokine und die neue ProPak GMP-Zytokinen-Linie, die voraussichtlich bis Ende 2024 kommerziell verfügbar sein wird.
- ScaleReady awarded a $150,000 grant to Verismo Therapeutics for cell therapy optimization
- The grant is part of a larger $20 million program to advance Cell and Gene Therapy development
- Potential for improved efficiency and cost-effectiveness in cell therapy production
- Early access to new closed system reagents (ProPak GMP Cytokines) from Bio-Techne
- None.
Insights
This grant marks a significant step for Verismo Therapeutics in optimizing their KIR-CAR platform using G-Rex technology. The
However, investors should note that Verismo is still in the clinical stage and the impact on their bottom line may not be immediate. The real value lies in the potential for scalable, cost-effective manufacturing of their novel CAR-T therapies, which could provide a competitive edge in the crowded cell therapy market. This grant might be a precursor to larger partnerships or investments in the future, signaling industry confidence in Verismo's technology.
The transition to G-Rex technology is a strategic move for Verismo. G-Rex systems are known for their high-density cell culture capabilities, which can significantly boost cell yields and reduce labor and materials costs. This could translate to more efficient production of Verismo's KIR-CAR T cells, potentially lowering the cost of goods (COGs) for their therapies.
The early access to Bio-Techne's ProPakTM GMP Cytokines is particularly intriguing. Closed-system reagents can enhance process consistency and reduce contamination risks, important factors in cell therapy manufacturing. If Verismo can successfully integrate these technologies, they may achieve a more robust and scalable manufacturing platform, positioning them favorably for future clinical trials and commercialization efforts.
The G-Rex Grant is part of ScaleReady's
"We are grateful to have been chosen for the G-Rex Grant at Verismo Therapeutics," stated Raymond Luke, Director of Manufacturing Science and Technology at Verismo Therapeutics. "This funding will help us further optimize our cell therapy manufacturing processes by transitioning our active and future pipeline to G-Rex®, ensuring we can deliver life-saving treatments to patients more efficiently and cost-effectively. We are excited to work with ScaleReady to drive forward innovative solutions in cell therapy production."
"We are excited to support Verismo Therapeutics through the G-Rex Grant program. Their commitment to advancing cell and gene therapy aligns perfectly with our mission to provide hope to cancer patients one G-Rex at a time. We look forward to seeing the impactful advancements Verismo Therapeutics will achieve with this grant." said John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of G-Rex.
As part of the G-Rex® Grant, Verismo will complete optimization of their G-Rex-based KIR-CAR T process and plans to implement this as a platform manufacturing process. Additionally, Verismo will evaluate a suite of critical reagents from Bio-Techne (R&D Systems) including GMP cytokines. Specifically, Verismo will get early access to a line of new, closed system reagents from Bio-Techne, called ProPakTM GMP Cytokines, that are tailor-made for use with G-Rex. The ProPakTM line of GMP cytokines are estimated to be commercially available by the end of 2024.
Verismo Therapeutics is committed to pioneering new therapies and technologies that improve patient outcomes. The G-Rex Grant will play a pivotal role in advancing the company's research and development efforts, ultimately contributing to the broader goal of making innovative treatments accessible to those in need.
About the KIR-CAR Platform
The KIR-CAR platform is a multi-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging tumor microenvironments. Using NK cell derived KIR and DAP12 split signaling provides a novel combined activation and co-stimulation separate from the usual T cell stimulation pathways. It also enables sustained chimeric receptor expression and improves KIR-CAR T cell long term function. This results in prolonged T cell functional persistence and leads to regression of solid tumors in preclinical models that are resistant to traditional CAR T cell therapies.
About Verismo Therapeutics
Verismo Therapeutics is a pioneer in multi-chain KIR-CAR technology, with its first assets SynKIR™-110 and SynKIR™-310 currently in Phase 1 clinical trials. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve persistence and efficacy against aggressive tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies. For more information, visit: www.verismotherapeutics.com
About ScaleReady™
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing Corporation
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-verismo-therapeutics-302249217.html
SOURCE Bio-Techne Corporation
FAQ
What is the value of the G-Rex Grant awarded to Verismo Therapeutics by ScaleReady?
How does the G-Rex Grant relate to Bio-Techne (NASDAQ: TECH)?
When are Bio-Techne's ProPak GMP Cytokines expected to be commercially available?
What is the total value of ScaleReady's grant program for Cell and Gene Therapy development?
